You are here

ST266

Noveome to assess ST266 to treat severe inflammatory response linked with COVID-19

Pharmaceutical Business Review

Tue, 03/31/20 - 11:08 am

Noveome Biotherapeutics

Noveome Biotherapeutics initiates trial evaluating intranasal delivery of ST266 targeting optic nerve and brain

Pharmaceutical Business Review

Fri, 09/27/19 - 10:44 am

Noveome Biotherapeutics

clinical tirals

intraocular hypertension